CRL: Charles River Laboratories Price to Earnings Adjusted for Growth Rate
The PEG ratio demonstrates the asset's value dynamics, where 2.23 forms the current metric value. Charles River Laboratories (CRL) dominates the preclinical testing and animal supply segment. Its status as a leading CRO ensures a stable cash flow and high-quality earnings. However, reductions in biotech budgets and strict regulatory oversight are creating certain pressure on the share price.
Analytical breakdowns for Charles River Laboratories (CRL)
The PEG ratio measures the efficiency of a stock's market value relative to its net income growth, where a value below one signals a fundamental undervaluation of the business. By analyzing the P/E ratio and the growth rates of Charles River Laboratories (CRL), an investor can identify entry points, taking into account the moderate dependence of Charles River Laboratories (CRL) on biotech R&D budgets and high resilience driven by long-term contracts with pharma behemoths.
